Premium
Immunogenicity study of low‐dose administration of hepatitis B virus vaccine in newborn infants: A cost reduction trial
Author(s) -
CHUNG WHAN KOOK,
CHOI KYU YONG,
LEE CHANG,
CHUNG JIN WU,
SUN HEE SIK,
CHUNG KYU WON,
KIM BOO SUNG,
CHUN CHUNG SIK,
CHO KYOO HONG,
KIM SEUNG JO
Publication year - 1987
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1987.tb00144.x
Subject(s) - medicine , seroconversion , hepatitis b vaccine , booster dose , immunogenicity , immunization , hbsag , pediatrics , hepatitis b , regimen , group b , hepatitis b virus , immunology , immune system , antibody , virus
Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg‐negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow‐up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely. Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age. While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization.